Turin, Italy — 29 June 2026 — Resalis Therapeutics, a Claris Ventures portfolio company developing RNA-based therapies for metabolic disorders, has dosed the first participant in a Phase 1b clinical study of its lead candidate, RES-010.
RES-010 is an investigational antisense oligonucleotide targeting microRNA-22 (miR-22). The approach aims to address metabolic dysfunction associated with obesity, with the goal of achieving durable, fat-selective weight loss while preserving lean mass.
A 12-week study in Australia
The randomised, placebo-controlled, sequential multiple-ascending-dose study is designed to enrol up to 36 healthy overweight and moderately obese adults at a single site in Australia. Up to three cohorts will receive once-weekly subcutaneous injections over 12 weeks, with the option of safety follow-up for up to six months.
The study will evaluate safety, tolerability and pharmacokinetics, alongside additional efficacy and pharmacodynamic endpoints. Assessments include body weight and other weight-loss-related parameters, as well as metabolic and inflammatory biomarkers to explore effects on lipid metabolism and fat tissue biology.
Advancing an RNA-based approach
According to Resalis, its first-in-human study showed that RES-010 was well tolerated and demonstrated early pharmacodynamic activity, including dose-dependent target engagement and reductions in body weight. The Phase 1b study will evaluate the candidate over a longer treatment period.
In its June announcement, Resalis said topline data were expected in late 2026. RES-010 remains in clinical development, and the intended benefits on durable weight loss and lean-mass preservation require further clinical validation.
Read the full press release (PDF) ↗
Source: Resalis Therapeutics press release, 29 June 2026. Image: AI-generated conceptual illustration of RNA and metabolic research.